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ORIGINAL ARTICLE
Fear of cancer recurrence in prostate cancer survivors
Marieke van de Wala, Inge van Oortb, Joost Schoutenb, Belinda Thewesa, Marieke Gielissena and Judith Prinsa
aDepartment of Medical Psychology, Radboud University Medical Center, Nijmegen, The Netherlands; bDepartment of Urology, Radboud
University Medical Center, Nijmegen, The Netherlands.
ABSTRACT
Background High fear of cancer recurrence (FCR) is an understudied topic in prostate cancer (PCa) sur-
vivors. This study aimed to detect the prevalence, consequences and characteristics associated with
high FCR in PCa survivors.
Material and methods This cross-sectional study included patients diagnosed with localized PCa and
treated with curative radical prostatectomy between 1992 and 2012. We administered the Cancer Worry
Scale (CWS) to assess FCR severity (primary outcome measure). Secondary outcomes included distress,
quality of life (QOL), post-traumatic symptoms, and multidimensional aspects of FCR. v2-tests, t-tests
and Pearson’s correlations examined the relationship between FCR and medical/demographic character-
istics. MANOVA analyses and v2-tests identified differences between PCa survivors with high and low
FCR.
Results Two hundred eighty-three PCa survivors (median age of 70.0 years) completed the question-
naires a median time of 7.1 years after surgery. About a third (36%) of all PCa survivors experienced
high FCR. High FCR was associated with lower QOL, more physical problems, higher distress and more
post-traumatic stress symptoms. PCa survivors with high FCR reported disease-related triggers (espe-
cially medical examinations), felt helpless and experienced problems in social relationships. High FCR
was associated with a younger age and having received adjuvant radiotherapy.
Conclusions Results illustrate that FCR is a significant problem in PCa survivors. Younger men and those
treated with adjuvant radiotherapy are especially at risk. Those with high FCR experience worse QOL
and higher symptom burden. Health care providers should pay specific attention to this problem and
provide appropriate psychosocial care when needed.
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Fear of cancer recurrence (FCR) is the fear or worry that the
disease will return or progress in the same organ or in
another part of the body [1,2]. It is hypothesized that normal
levels of FCR promote adequate threat monitoring behavior
[3] whereas studies found that high FCR is associated with
functional impairment [4], lower quality of life (QOL), distress
and reassurance seeking behavior (e.g. extra medical exami-
nations) [5–7]. Due to the use of different assessment instru-
ments, reported prevalence of FCR amongst cancer survivors
ranges between 39% and 97% [6].
FCR in PCa survivors has been described in some studies
[6,8–12], but only one study has reported the prevalence of
high FCR using a validated cutoff score [12]. While mean lev-
els of FCR were found to be lower in PCa survivors compared
to those with breast, colorectal or lung cancer [2,6]; the
prevalence of high FCR was higher in PCa survivors (32%,
n¼ 23) than colorectal cancer survivors (24%, n¼ 10), but
lower than in breast cancer survivors (40%, n¼ 23) (signifi-
cance testing was not conducted). Larger scale studies are
needed to provide more insight in the prevalence and factors
associated with high FCR in PCa survivors.
One might expect a lower prevalence of high FCR in PCa
survivors than in other cancer types as PCa is considered as
one of the most curable forms of cancer: most PCa patients
present with early stage disease (I–II), the five-year relative
survival rate in this group is nearly 100% and the prognosis
following a recurrence is still relatively good [13]. In contrast
to the PCa population, high FCR is associated with female
gender and younger age [6,14].
Clinical practice suggests that PCa specific factors might
contribute to FCR. For example, the regular monitoring of
prostate-specific antigen (PSA) levels in the blood. From the
patient perspective, rising levels signals increasing PCa activ-
ity. PSA testing is therefore both clinically and psychologically
meaningful for survivors and the uncertainty that comes with
rising PSA might trigger FCR.
Greater knowledge of factors associated with FCR in PCa
survivors can be used to inform intervention development
and improve care. Currently, there is little data on the antece-
dents, triggers and consequences of FCR, or factors associated
with high FCR in the PCa population. The aims of this study
were to identify: 1) the prevalence (and characteristics) of
FCR; 2) the consequences of clinical FCR; 3) medical character-
istics and demographics associated with FCR; and 4) to
explore the relationship between PSA testing and FCR
amongst PCa survivors who underwent curative treatment.
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Eligible patients were: 1) diagnosed with localized prostate
adenocarcinoma; and 2) treated with curative radical prosta-
tectomy (RP) [optional: radiotherapy (RT)] between 1992
and 2012. Patients were excluded if they received hormone
therapy. Eligible patients were identified by a urologist (IvO)
between June and August 2013 from a patient database
managed by the Department of Urology, Radboudumc.
Deceased patients were identified and removed by Dutch
Cancer Registry data linkage. Eligible patients received a
mailed study information and invitation to participate
from the Department of Urology. Consenting patients
returned a written informed consent form and completed
either an online or paper and pencil questionnaire. Ethical
approval was given by the Medical Ethics Committee,
Radboudumc.
Instruments
Demographic and medical characteristics
Demographics, number of comorbid conditions and months
until next medical follow-up were gathered by self-report.
Treatment modality, PSA level, time since last PSA test were
obtained from medical records. We were not able to specify
patients with a disease recurrence. Due to length of time
since diagnosis (up to 20 years), data on recurrence status
was unavailable in the hospital database used to identify
participants.
Fear of cancer recurrence: severity
Cancer Worry Scale: FCR severity was measured with the
Cancer Worry Scale (CWS). The CWS consists of eight items
ranging from 1 (‘never’) to 4 (‘almost always’). Scores range
from 8 to 32, a higher score indicating more FCR. A score of
14 is optimal for differentiating between high and low FCR
in breast cancer survivors [15]. To determine the optimal cut-
off point, and to evaluate the accuracy of the CWS in identify-
ing PCa survivors with low versus high FCR, a receiver
operating characteristic (ROC) analysis with the eight-item
CWS and the Fear of Cancer Recurrence Inventory – Severity
subscale (FCRI-Severity) was performed (using the clinical cut-
off score of 16 to indicate high FCR) [12]. The area under
the curve was 0.93 (p< 0.001; 95% CI 0.89–0.96) (Appendix 1,
available online at http://www.informahealthcare.com), which
represents a good level of discrimination. In order to correctly
differentiate PCa survivors with high FCR, from those with
low FCR, a cutoff which optimizes sensitivity and specificity
was selected. To differentiate between high FCR and low FCR
a cutoff point of 12 versus 13 (low:12, high13) had the
best performance with a sensitivity of 86%, a specificity of
84%, a positive predictive value of 71% and a negative pre-
dictive value of 93% (Appendix 2, available online at http://
www.informahealthcare.com). The internal consistency of the
CWS was high (Cronbach’s a¼ 0.88). The correlation between
the CWS and the FCRI-Severity subscale was r¼ 0.83 and in
87% of the cases both the CWS and FCRI-Severity subscale
agreed on the presence or absence of FCR. Cohen’s kappa
was 0.67 (SE 0.05). which corresponds to a substantial degree
of agreement between measures.
Fear of cancer recurrence: Multidimensional aspects
The 42-item Fear of Cancer Recurrence Inventory (FCRI) is a
psychometrically sound questionnaire used to assess multidi-
mensional aspects of FCR [2,12]. Seven subscales were used:
Triggers (8-items), Severity (9-items), Psychological Distress
(4-items), Functioning Impairments (6-items), Insight (3-items),
Reassurance seeking (3-items) and Coping (9-items). All items
were scored on a scale from 0 (‘not at all’ or ‘never’) to 4
(‘a great deal’ or ‘all the time’) [2,12].
PSA-related anxiety
The three-item PSA Anxiety Scale of the Memorial Anxiety
Scale for Prostate Cancer (MAX-PC) was selected to measure
anxiety related to PSA [16]. All items were answerable on a 0
(‘not at all’) to 3 (‘often’) scale (a¼0.56).
Distress
The Hospital Anxiety and Depression Scale (HADS) is a 14-item
self-report questionnaire frequently used to screen for dis-
tress. The HADS has a 7-item anxiety and a 7-item depression
subscale, all items are scored on a 0 (‘never’) to 3 (‘almost
always’) scale; with a HADS total score ranging from 0 (no dis-
tress) – 42 (maximal distress) [17].
The Impact of Events Scale (IES) measures cancer-related dis-
tress and the extent to which patients experience intrusive
thoughts about cancer (7-items) and avoid thinking about
cancer (8-items). Total scores range from 0 to 75 (severe dis-
tress) [18].
Quality of life
QoL was assessed with the 30-item European Organization
for Research and Treatment of Cancer Quality of Life
Questionnaire (EORTC QLQ-C30) and PCa specific module
(EORTC QLQ-PR25) [19,20]. The EORTC QLQ-C30 provides one
global health status/QoL scale score and five functional scale
scores. The QLQ-PR25 assesses sexual functioning and disease
and treatment-related symptoms [19]. All scale scores were
transformed to a 0–100 scale. A higher functional scale score
reflects a better level of functioning, a higher symptom score
indicates more severe symptoms [21].
Data analyses
SPSS20 was used for analyses. Relevant data were screened
for normality and outliers. Descriptive statistics were used to
describe the medical and demographic characteristics of the
sample. Incomplete data for the CWS were recorded as miss-
ing and excluded from analysis. Unless otherwise specified, all
analyses were done at an alpha0.05 level of significance.
v2-tests, t-tests and Pearson’s correlations were performed to






























test the relationship between FCR (continuous score) and
demographic (age at diagnosis, age at survey, partner status,
children, education) and medical characteristics (years since
diagnosis, years since surgery, treatment received, number of
comorbidity, familiar PCa, PSA level, days since PSA-test and
days until next medical appointment). For subsequent analy-
ses the CWS cutoff score was used to group patients accord-
ing to low or high FCR (low:12; high13; see
measurements CWS). Multidimensional aspects of FCR (meas-
ured with the FCRI) and psychological variables (Distress, QoL)
were compared between the high versus low FCR group with
MANOVAs. For a descriptive analysis of the FCRI and MAX-PC
PSA anxiety scores, percentages of responses to the individual




In total, 740 men met eligibility criteria and were asked to
participate (see Figure 1). In total 504 responded (68%) of
whom 391 agreed to participate (53%). Reasons for non-par-
ticipation are displayed in Figure 1. Questionnaires were com-
pleted and returned by 318 survivors (43%). Twenty-eight
falsely included PCa survivors were excluded because they
received hormone therapy (n¼ 24) or were diagnosed prior
to 1992 (n¼ 4). Five PCa survivors did not complete the CWS
and two questionnaires were completed by someone other
than the patient. Eventually, data of 283 patients were ana-
lyzed (38%). Data on non-responders, decliners or non-com-
pleters were unavailable.
Patient characteristics
Information about demographic, disease and treatment char-
acteristics of the participants are listed in Table 1. All PCa sur-
vivors received curative RP treatment with a median time
since diagnosis of 7.9 years (range 0.9–20). Twenty-seven per-
cent received additional RT (with curative intent). Median age
at survey was 70.0 years (range 54–89).
Prevalence of high FCR
Mean CWS score of the total sample was 12.0 (SD¼ 3.7) and
104 PCa survivors (36%) met the cutoff criterion for high FCR.
Mean CWS score for high fearful survivors was 15.8 (SD¼ 3.3),
and 9.8 (SD¼ 1.4) for low fearful survivors [t (281)¼21.44;
p< 0.001].
Multidimensional aspects of FCR
PCa survivors with high FCR reported significantly more trig-
gers, distress and functional impairments, insight and reassur-
ance seeking behavior than those with low FCR (Table 2).
Item analysis of the FCRI subscales between low and high
fearful survivors is shown in Table 3.
Psychosocial characteristics associated with high and
low FCR
Distress: PCa survivors with high FCR reported significantly
higher distress, depression, anxiety, intrusive thoughts and
signs of avoidance (p< 0.001).
QoL: PCa survivors with high FCR reported significantly worse
emotional functioning, global health and social functioning
(all p< 0.05). Furthermore, those with high FCR reported
more urinary symptoms (p¼ 0.007), more bowel symptoms
(p< 0.001) and more treatment-related problems (p¼ 0.003)
(Table 2). All differences were small in magnitude (<10
points) and thereby of minimal clinical significance.
Medical and demographic characteristics associated with
high and low FCR
A younger age was significantly associated with higher FCR
(p¼ 0.03) (Table 1). In addition, PCa survivors with high FCR
had more often received adjuvant RT than those reporting
low FCR (37% vs. 21%; v2¼8.18; p¼ 0.004). No significant
associations were observed concerning the other demograph-
ics/medical characteristics.
PSA testing and FCR
Last measured PSA level, number of days since last PSA test
and number of days to next medical follow-up, were not sig-
nificantly associated with FCR (Table 1). PCa survivors with
high FCR reported significantly more PSA-related anxiety
(p< 0.001). Individual items of the three-item PSA-Anxiety
Scale indicated that 6% of the high fearful compared with 1%
of the low fearful survivors had considered delaying their PSA
test due to FCR (v2¼7.255; p¼ 0.007). Four percent of high
FCR survivors considered having the test repeated at another
laboratory compared with 2% of the low fearful survivors
(v2¼1.230; p¼ 0.267). Finally, 6% thought about having their
own doctor repeat the test, compared with 2% of survivors
with low FCR (v2¼3.47; p¼ 0.06).
Discussion
The first aim of this study was to investigate the prevalence
of FCR in a large sample of PCa survivors. Approximately one-
third (36%) of the sample displayed high FCR as defined by a
score of 13 or higher on the CWS. This prevalence is similar
to that reported in studies of breast (31%) and colorectal can-
cer survivors (38%) also using the CWS [15,22], and supports
the findings of Simard et al. (2015) (32% of PCa survivors)
who used the FCRI [12]. Despite the relatively favorable prog-
nosis, high FCR remains a significant problem in a substantial
minority of PCa survivors even years after diagnosis.
QoL differed significantly between participants who experi-
enced high and low FCR, those with high FCR having a lower
global health, poorer emotional functioning and social func-
tioning. Furthermore, they experienced more problems with
urinary, bowel and treatment-related symptoms. Findings































Figure 1. Patient recruitment flowchart.
Table 1. Demographic, medical characteristics and their association with FCR (n¼ 283).
N (%) Mean CWS (range 8–32) Test statistic; p-value
Age at diagnosis (years) Median 62.5 (range 39–76) – r¼ –0.09; p¼ 0.146
Age at survey (years) Median 70.0 (range 54–89) – r¼ –0.13; p¼ 0.025*
Partner
Yes 255 (91%) 11.9 (3.6) t¼ 1.374; p¼ 0.171
No 25 (9%) 13.0 (4.8)
Children
Yes 259 (92%) 12.0 (3.7) t¼ 0.465; p¼ 0.642
No 23 (8%) 12.4 (3.8)
Education
Low 69 (27%) 12.1 (3.4)
Middle 75 (28%) 11.8 (4.0) F¼ 0.233; p¼ 0.793
High 121 (45%) 12.2 (3.8)
Years since diagnosis Median 7.9 (range 0.9–20) – r¼ –0.10; p¼ 0.102
Years since surgery Median 7.1 (range 0.7–20) – r¼ –0.11; p¼ 0.086
Treatment
Surgery only 206 (73%) 11.8 (3.7) t¼ –2.033; p¼ 0.043*
Surgeryþ RT 75 (27%) 12.8 (3.7)
Comorbidity
none 65 (23%) 11.6 (3.2) F¼ 0.591; p¼ 0.621
1–2 160 (56%) 12.1 (3.4)
3–4 49 (18%) 12.5 (4.8)
>4 8 (3%) 11.9 (4.6)
Familiar PCa
No relatives with PCa 205 (73%) 12.0 (3.9) t¼ 0.729; p¼ 0.467
Father, brother or both with PCa 77 (27%) 11.7 (3.0)
PSA level
0 or 0.1 247 (90%) 11.8 (3.7) F¼ 1.061; p¼ 0.348
>0.1–0.2 11 (4%) 13.5 (3.4)
>0.2 17 (6%) 12.2 (3.4)
Days since PSA test Median 118.0 (range 4–3249) r¼ –0.05; p¼ 0.475
Days until next medical appointmenta Median 79.0 (range 0–365) r¼ –0.04; p¼ 0.579
FU, follow-up; PCa, prostate cancer; PSA test, prostate-specific antigen test; RT, radiotherapy.
an¼ 174: not all PCa survivors had already scheduled their next appointment. *p¼ 0.05






























experienced more depression, anxiety, post-traumatic symp-
toms (intrusive thoughts, avoidance) and were significantly
more distressed than those with low fear. Although direction-
ality of the relationship cannot be determined, healthcare
professionals should be aware of high FCR in clinical practice,
as it is associated with adverse outcomes in terms of both
physical and emotional well being.
Interestingly, of those with high FCR only a small propor-
tion reported disturbances in functioning (11–12%) and most
survivors did not feel that they worried excessively about a
possible recurrence (87%). So, despite the association of high
FCR with negative health outcomes (QoL, treatment-related
symptoms), item analysis seems to indicate that FCR is con-
sidered a manageable concern for most fearful PCa survivors.
However, compared with low fearful survivors those with
high FCR reported significantly higher percentages of distur-
bances in functioning or distress due to FCR.
In line with earlier studies, involving other cancer types,
medical examinations were identified as an important trigger of
FCR by high fearful PCa survivors (41%) [4,22,23]. Despite that
high FCR has also often been associated with bodily checking
and self-monitoring of symptoms [3,14], this was not the case
in our study. Bodily checking did not occur frequently in high
fearful PCa survivors. A possible explanation for this finding is
that rising PSA levels are typically the first sign of a recurrence,
well before any clinical signs are present. Bodily checking is
therefore less relevant for PCa survivors than for other cancer
types (e.g. breast cancer). Time since diagnosis, last PSA test,
and time until next medical follow-up were not associated with
FCR. Nor was last measured PSA level associated with FCR. Our
results imply that high FCR is stable over time and is not neces-
sarily influenced by disease-specific events, such as PSA testing.
However, due to the cross-sectional study design, longitudinal,
prospective studies are needed in order to establish trajectories
of FCR before and after PSA testing.
Demographics and medical variables significantly associ-
ated with higher FCR were a younger age and adjuvant RT. A
younger age has more often been associated with high FCR
in other cancer types [6,7,14]. For PCa survivors, it could be
that those who are younger experience more life disruption
caused by cancer (e.g. concerning employment problems,
financial responsibility), which may increase their vulnerability
to FCR. However, reasons for the association with age are still
speculative and lend themselves to further exploration in
qualitative studies.
PCa survivors who received adjuvant RT following surgery
reported higher FCR than those treated with surgery only.
This is consistent with two other studies where RT or brachy-
therapy was associated with higher FCR in a sample of mixed
cancer types [2] and PCa survivors [10]. A possible explan-
ation for the association between FCR and treatment modality
is that the relationship between RT and FCR is mediated by
recurrence status. In the academic center where our sample
was recruited RT is only considered for treatment when PCa
shows a recurrence and medical intervention is needed. Thus,
those patients who were treated with RT have all experienced
a (biochemical) disease recurrence prior to completion of
questionnaire. It has previously been shown that having had
a disease recurrence is in itself an independent risk factor for
developing high FCR [24]. Unfortunately, due to absence of
data it was not possible to specify recurrence status as an
explicit variable in current study.
Some limitations of this study should be noted. First, due
to the cross-sectional nature of this study our results do not
imply causation. Longitudinal studies are needed to ascertain
causality. Second, 6% of the PSA levels were>0.2: which is
indicative of a current biochemical disease recurrence. At
time of inclusion these individuals did not receive any med-
ical intervention and were included. However, due to the
relatively low number of those with heightened PSA levels
we believe this had only a negligible impact on our findings.
Third, all PCa survivors were selected from a database in an
academic center and the response rate was low (38%).
Literature shows that patients in non-academic medical cen-
ters differ from those who visit academic medical centers
(the latter are often younger and have a better socioeco-
nomic status) [25] and results might not be representative
off all PCa survivors. Additionally, even though the study
information made it clear the study was for everyone regard-
less of level of FCR, the main reason for non-participation in
this study was the self-reported absence of FCR (n¼ 23). Our
aim was to include all eligible survivors and not only those
bothered by high FCR. Therefore, the percentage of PCa sur-
vivors experiencing high FCR could be overestimated due to
self-selection bias. Fourth, as in most other self-report ques-
tionnaire studies, there is no guarantee that all returned
Table 2. Differences in psychosocial functioning by low versus high FCR.
Low FCR (n¼ 179) High FCR (n¼ 104) p-value
EORTC QLQ-C30 Mean (SD) Mean (SD)
Global health/QoL 83.5 (15.1) 75.6 (17.4) <0.001**
Physical functioning 89.3 (14.9) 88.1 (15.0) 0.528
Role functioning 89.2 (19.3) 84.0 (24.0) 0.050
Emotional functioning 92.7 (12.3) 85.5 (16.2) <0.001**
Cognitive functioning 88.7 (17.0) 84.7 (19.1) 0.069
Social functioning 92.8 (15.4) 86.8 (21.9) 0.009**
EORTC QLQ-PR25
Sexual activity 55.5 (17.4) 59.3 (17.6) 0.248
Sexual functioning 49.6 (24.7) 53.5 (24.7) 0.407
Urinary symptoms 12.6 (11.1) 19.4 (15.2) 0.007**
Bowel symptoms 1.9 (4.7) 7.5 (10.5) <0.001**
Hormonal/treatment 7.3 (6.3) 11.5 (8.8) 0.003**
Incontinence aid 19.1 (16.6) 23.7 (15.2) 0.310
HADS
Total 3.9 (4.2) 8.6 (6.2) <0.001**
Anxiety 1.8 (2.2) 4.4 (3.3) <0.001**
Depression 2.1 (2.6) 4.3 (3.6) <0.001**
FCRI
Severity 7.2 (4.8) 19.9 (7.8) <0.001**
Triggers 6.1 (5.1) 14.2 (6.3) <0.001**
Distress 1.8 (2.3) 5.4 (3.5) <0.001**
Impairments 0.7 (1.7) 4.9 (5.4) <0.001**
Insight 0.1 (0.3) 1.4 (2.0) <0.001**
Reassurance 1.0 (2.3) 1.9 (2.3) 0.002**
IES
Total 2.0 (5.3) 11.5 (13.9) <0.001**
Avoidance 1.1 (3.1) 6.1 (8.3) <0.001**
Intrusion 0.9 (3.0) 5.2 (6.3) <0.001**
MAX-PC
PSA-Anxiety Scale 0.2 (0.8) 0.7 (1.7) <0.001**
Differences in QLQ-C30 and QLQ-PR25 scores of 5–10, >10–20 and >20 were
defined as ‘minimally’, ‘moderately’ and ‘largely’ clinically significant.































questionnaires were completed by the addressed patient
and not someone else. An introductory letter was attached
to the questionnaire booklet asking the patient to fill-out the
questionnaire themselves and it was assumed that the
patient completed the questionnaire unless otherwise speci-
fied. Finally, the CWS was used to differentiate between high
and low fearful PCa survivors. Only estimates of reliability
and criterion validity were established in this study and
other aspects of validity were beyond the scope of this
study.
This study showed that high FCR is a significant problem
in more than a third of all PCa survivors. Younger patients
and those treated with adjuvant RT are most vulnerable to
high FCR. While medical examinations are triggers of FCR in
themselves, FCR was not found to be influenced by PSA level,
time since last PSA test, or time until next medical follow-up.
PCa survivors with high FCR reported worse emotional well
being and experienced more disease- and treatment-related
symptoms even years after completion of treatment.
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Quality of life 11% 2%*
Future planning 11% 0%*
Reassurance
Calling a doctor/other health professional 7% 6%
Going to the hospital/clinical for examination 7% 6%
Self-examination for physical signs of a recurrence 4% 3%
Coping
Trying to think positively 33% 30%
Trying to understand what is happening and how to deal with it 30% 23%
Trying to replace the thought with a more pleasant one 28% 17%
Severitya
Unpleasant thoughts or images (e.g. death, suffering) when thinking about a recurrence 33% 5%*
The belief that it is normal to be anxious or worried about potential cancer recurrence 28% 10%*
Insightb
The extent to which you feel that you worry excessively about a potential recurrence 87% 100%*
The extent to which other people think you worry excessively about a potential recurrence 91% 100%*
aSeverity: answer categories ‘Often/Very often’;
binsight: answer categories ‘Not at all/A little’.
*To correct for multiple testing p< 0.001 was classified as indicating a significant difference between scores.
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